Skip to content

Altimmune ALT Book value per share

Book value per share at other companies

Eli Lilly logo
Eli LillyLLY
$34.82+98.9%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$18.72-26.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$4.34-42.5%
Wave Life Sciences logo
Wave Life SciencesWVE
$2.56+142%
Delcath Systems logo
Delcath SystemsDCTH
$3.13+54.1%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$0.72-271%

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K
Free cash flow-$21.0M

Valuation

See full
Market cap$558.14M-2.1%
Enterprise value$495.27M-5.0%
P/S13,613.2×-24,380×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Calculated from Altimmune’s reported figures.

Based on the most recent quarter.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Altimmune's book value per share?
Altimmune (ALT) reported book value per share of $2.28 in Q1 2026.
How has Altimmune's book value per share changed year-over-year?
Altimmune's book value per share increased by 21.3% year-over-year, from $1.88 to $2.28.
What is the long-term trend for Altimmune's book value per share?
Over 5 years (2020 to 2025), Altimmune's book value per share has grown at a -21.9% compound annual growth rate (CAGR), from $8.81 to $2.55.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.